J Drugs Dermatol. 2023 Aug 1;22(8):761-765. doi: 10.36849/jdd.7481.
Psoriasis is a chronic, immune-mediated, multisystem, inflammatory dermatological condition that is persistent and relapsing. Topical treatments are first line agents for mild to moderate plaque psoriasis. With proven efficacy and safety, topical corticosteroids are often used, although adverse effects and limitations for use exist. Tapinarof (Vtama®), a novel topical aryl hydrocarbon receptor modulating drug, was approved by the US Food and Drug Administration for the treatment of plaque psoriasis in adults in May 2022. A literature search of PubMed, MEDLINE, and ClinicalTrials.gov was conducted using the following keywords: tapinarof, psoriasis, GSK2894512. Articles published before January 2023 were included in this review. This review describes the preclinical and clinical studies demonstrating the efficacy and safety of tapinarof, its place in therapy, and relevance to patient care. Kalabalik-Hoganson J, Nogid A, Frey K. A review of tapinarof: novel topical treatment for plaque psoriasis in adults. J Drugs Dermatol. 2023;22(8):761-765. doi:10.36849/JDD.7481.
银屑病是一种慢性、免疫介导的、多系统炎症性皮肤病，具有持续性和复发性。局部治疗是轻度至中度斑块型银屑病的一线药物。局部皮质类固醇具有良好的疗效和安全性，因此经常被使用，但也存在不良反应和使用限制。Tapinarof（Vtama®）是一种新型的局部芳香烃受体调节剂药物，于 2022 年 5 月被美国食品和药物管理局批准用于治疗成人斑块型银屑病。本综述通过使用以下关键词在 PubMed、MEDLINE 和 ClinicalTrials.gov 上进行了文献检索：tapinarof、psoriasis、GSK2894512。纳入了发表于 2023 年 1 月之前的文章。本综述描述了证明 tapinarof 疗效和安全性的临床前和临床研究，及其在治疗中的地位，以及与患者护理的相关性。Kalabalik-Hoganson J, Nogid A, Frey K. A review of tapinarof: novel topical treatment for plaque psoriasis in adults. J Drugs Dermatol. 2023;22(8):761-765. doi:10.36849/JDD.7481.
